Key result
In-hospital semaglutide with nurse titration linked to ~10-point higher 30-day quality of life-12 scores vs. usual care.
Why the study?
In obesity-associated HFpEF, anti-obesity therapy after discharge is commonly deferred due to scarce early outpatient slots and travel barriers, and dose escalation rarely happens without a proactive contact plan. Whether in-hospital semaglutide initiation followed by a structured 30-day nurse titration protocol improves early health status versus usual discharge care was tested.
Does in-hospital initiation of semaglutide with a structured 30-day nurse titration protocol improve early health status (KCCQ-12) at 30 days compared to usual discharge care in hospitalized adults with obesity-associated HFpEF?
Cohort (n=412)
Does in-hospital initiation of semaglutide with a structured 30-day nurse titration protocol improve early health status (KCCQ-12) at 30 days compared to usual discharge care in hospitalized adults with obesity-associated HFpEF?
In-hospital initiation of semaglutide paired with a 30-day nurse titration protocol significantly improved 30-day health status (KCCQ-12), increased short-term weight loss, and lowered 30-day readmissions compared to usual discharge care in patients with obesity-associated HFpEF.
Answers are grounded in this paper and cite their sources.
May support early semaglutide initiation with nurse titration in obesity-associated HFpEF; hypothesis-generating and requires randomized confirmation before practice change.
Background In obesity-associated heart failure with preserved ejection fraction (HFpEF), the usual failure mode after discharge is not lack of intent—it is delay. In our ward workflow, anti-obesity therapy was commonly deferred because early outpatient slots were scarce, travel barriers were real, and dose escalation rarely happened without a proactive contact plan. Purpose To test whether starting semaglutide during hospitalisation, then handing off titration to a structured 30-day nurse protocol, improves early health status versus usual discharge care. Methods Pragmatic prospective cohort design. Of 526 screened admissions, 412 eligible adults were enrolled (pathway n=218; usual care n=194). We chose a 30-day primary window because it matches the "vulnerable month" when congestion, adherence, and access problems cluster—and when a missed start often becomes a missed year. The pathway was offered when a trained nurse-titration slot and phone follow-up capacity were available at discharge; otherwise, patients received usual care. Semaglutide was selected for once-weekly dosing (simpler logistics during transition) and a predictable escalation schedule. Primary endpoint: change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) from discharge to day 30. Prespecified regression models adjusted for age, sex, body mass index, diabetes, atrial fibrillation, and baseline KCCQ-12. Results Thirty-day KCCQ-12 was obtained in 365/412 (88.6%). Semaglutide initiation before discharge occurred in 210/218 (96.3%) in the pathway group. Mean KCCQ-12 change was 20.0 (SD 8.9) with the pathway versus 10.0 (SD 9.7) with usual care (adjusted difference 10.0 points, 95% CI 7.6–12.4; P<0.001). Weight change was −5.4 (SD 3.0) kg versus −1.5 (SD 2.7) kg (adjusted difference −4.0 kg, 95% CI −4.6 to −3.4; P<0.001); ≥5% weight loss occurred in 113/195 (57.9%) versus 19/170 (11.2%). Thirty-day readmission occurred in 16/218 (7.3%) versus 27/194 (13.9%) (adjusted OR 0.51, 95% CI 0.26–0.99). Among initiators, discontinuation by day 30 was uncommon (11/210 [5.2%] vs 3/49 [6.1%]). Conclusion Starting semaglutide in hospital and owning the first month with nurse titration produced a larger early health-status gain and greater short-term weight reduction than usual discharge care. Here’s the trade-off: it front-loads work into discharge week and the first 30 days, but it avoids the more common—and costly—alternative of delayed initiation and stalled escalation.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a cohort in Obesity-associated heart failure with preserved ejection fraction (HFpEF) (n=412). In-hospital semaglutide initiation with 30-day structured nurse titration protocol vs. Usual discharge care was evaluated on Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) from discharge to day 30 (MD 10.0, 95% CI 7.6-12.4, p=<0.001). In-hospital semaglutide with 30-day nurse titration improved 30-day quality of life-12 scores more than usual care.
Synapse has enriched 10 related papers. Consider them for comparative context: